The9's Investee Nanyang Biologics Targets Public Listing to Revolutionize Drug Discovery.

Nanyang Biologics Sets Course for Public Listing, Aiming to Transform Drug Discovery

Nanyang Biologics Pte. Ltd. (NYB), an investee company of The9 Limited, is poised for a significant transformation as it enters into a business combination agreement with RF Acquisition Corp II. This strategic move enables NYB to become a publicly listed entity, with an anticipated pre-transaction equity value of around $1.5 billion. The agreement has already received approval from both companies' boards, and the merger is expected to finalize in the first or second quarter of 2026, pending shareholder approval and customary closing conditions. This venture marks a pivotal moment for NYB, as it seeks to enhance its capabilities in drug discovery through innovative methods.

Following the merger, NYB plans to leverage its advanced artificial intelligence platform to streamline the identification of effective drug molecules and natural ingredients for pharmaceuticals and traditional medicine. This technological approach aims to improve the efficiency and efficacy of drug development processes, ultimately leading to better healthcare outcomes. NYB's commitment to innovation is evident, particularly after winning 1st Prize at the SuperAI Genesis Startup Competition 2025, where it stood out among over 700 regional competitors. This recognition underscores NYB's potential to disrupt the biopharmaceutical landscape and underscores the company's capacity for groundbreaking advancements.

Moreover, NYB's collaboration with industry giants such as Nvidia, Hewlett Packard Enterprise, and Equinix highlights its ambition to construct the world's largest natural compound library. This partnership focuses on developing scalable AI platforms for drug discovery and establishing secure infrastructure for healthcare innovations. This initiative emphasizes the critical need for robust digital infrastructure to protect sensitive scientific data, which is vital in drug development involving biopharmaceuticals and molecular screening models. NYB is also expanding its portfolio of patents related to its drug-candidate pipeline and proprietary nutraceuticals, with ongoing efforts to develop first-in-class therapeutic solutions that could redefine treatment paradigms.

In addition to the merger, NYB is structured to ensure that existing shareholders, including The9, maintain a majority stake in the new entity. This strategic positioning not only provides stability but also aligns the interests of The9 with NYB's long-term goals. The proposed changes mark an exciting chapter for both companies, with a shared vision of advancing drug discovery and healthcare innovations through technology and collaboration.